Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Host: Jhanelle E. Gray, MD
\n\n\n \n
In this video series, learners will explore best practices for the use of immunotherapies in unresectable stage III NSCLC, including staging, determining resectability, applying clinical data, and managing toxicities.